| Date | Title | Description |
| 17.07.2025 | GenSight Biologics Raises Approx. EUR 500K | GenSight Biologics, a Paris, France-based biopharma company focused on developing and commercializing gene therapies for retinal neurodegenerative diseases and central nervous system disorders, raised approximately EUR 500K.
Backers were no... |
| 28.02.2023 | GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON) | GenSight Biologics, a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, highlights its commitment to fight rare neurodegenerati... |
| 20.01.2022 | GenSight Biologics S A : Corporate presentation, January 2022 | Corporate Presentation
January 2022
A LEADING Gene Therapy BIOTECHNOLOGY COMPANY
GENSIGHT-BIOLOGICS.COM
Disclaimer
This document contains forward-looking statements and estimates made by the GenSight Biologics S.A. (the "Company")... |
| 29.03.2021 | GENSIGHT BIOLOGICS S.A.
GenSight Biologics S A : successfully raises EUR30 million in an oversubscribed private placement with European and US institutional investors | Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central n... |
| 26.03.2021 | GENSIGHT BIOLOGICS S.A.
GenSight Biologics S A : launches a reserved offering of c. EUR25 million by means of an accelerated book building process | Paris - GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the 'Company'), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central n... |
| 30.07.2020 | GENSIGHT BIOLOGICS S.A.
GenSight Biologics S A : 2020 Half-Year Financial Report | HALF-YEAR FINANCIAL REPORT
JUNE 30, 2020
TABLE OF CONTENTS
CONDENSED HALF-YEAR CONSOLIDATED FINANCIAL STATEMENTS 3
ACTIVITY REPORT 25
TRANSACTIONS BETWEEN RELATED PARTIES 29
RISK FACTORS 31
STATUTORY AUDITORS' REVIEW REPORT ON THE 2020 HALF... |
| 04.04.2018 | A gene therapy mystery? GenSight blasted as 1st PhIII eye study ends in an intriguing failure | GenSight has a gene therapy mystery on its hands, which is about the last thing it wanted at the end of Phase III.
Assessing the 48-week data from its first pivotal test of a treatment for Leber Hereditary Optic Neuropathy — ... |
| 23.06.2017 | Merck KGaA gets a thumbs up for once-dead MS drug; Aveo shares soar as tivo makes a comeback | → Cladribine is back. Once given up for dead by Merck KGaA, the multiple sclerosis drug has been endorsed by the CHMP in Europe, setting up a likely approval. Longtime Merck KGaA watchers will recall that Merck killed the p... |
| 23.06.2017 | Novartis-backed GenSight gets cash for gene therapy launch | GenSight Biologics has raised (PDF) €22.5 million ($25.2 million) to prepare to bring gene therapy GS010 to market in the U.S. and Europe. The financing gives the Novartis-backed biotech enough cash to deliver data from two phase 3 trials n... |
| 23.07.2015 | GenSight Biologics Completes $36M Series B Financing | GenSight Biologics S.A., a Paris, France-based clinical-stage biotechnology company, completed a $36m Series B financing.
Backers included new investors Fidelity Management & Research Company, Jennison Associates (on behalf of certain c... |
| 23.07.2015 | Daily funding roundup - July 23, 2015 | Flipboard raised $50M; Notion Capital launched $120M; CarPrice closed $40M
CarPrice wants to be the company that brings the process of buying used cars in Russia online closed $40 million in Series B funding. The round was led by Baring Vos... |
| 08.04.2013 | GenSight Biologics Inks EURO32M in Series A |
PARIS, FRANCE, Biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, announced today the closing of a EURO32 million Series A financing.
>> Click here for more funding data on GenSight ... |
| 08.04.2013 | GenSight Biologics Closes €32M Series A Financing | GenSight Biologics, a Paris, France-based biopharmaceutical company focused on the development of ophthalmic therapeutics using gene therapy, closed a €32m Series A financing.
The round was co-led by Novartis Venture Fund, Abingworth LLP, V... |
| - | Intravitreal administration of GS010 in patients with LHON was safe and well tolerated | Paris, France, February 12, 2019, 7:30 a.m. CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative ... |
| - | GenSight Biologics reports positive 72-week data from REVERSE Phase III clinical trial of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) | • Clinically meaningful improvement of +15 ETDRS letters in visual acuity of treated eyes at Week 72
• Continuous bilateral improvement of both visual acuity and contrast sensitivity
• Significantly higher proportion of drug-treated eyes ... |
| - | Sustained bilateral improvement from GenSight Biologics’ REVERSE Phase III clinical trial represents transformative therapeutic benefit for patients, Key Opinion Leaders conclude | Paris, France, May 29, 2019, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseas... |
| - | GenSight Biologics reports positive additional data from REVERSE Phase III clinical trial of GS010 for treatment of Leber Hereditary Optic Neuropathy (LHON) | Paris, France, June 12, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disea... |
| - | GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020 | Paris, France, March 12, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disea... |
| - | GenSight Biologics Reports its Cash Position as of December 31, 2019 and Provides Operational Update | Paris, France, January 21, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative dis... |
| - | GenSight Biologics Reports Cash Position as of September 30, 2020 and Provides Operational Update | Paris, France, October 15, 2020, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerativ... |
| - | GenSight Biologics receives MHRA approval to initiate Phase I/II PIONEER clinical trial of GS030 gene therapy in Retinitis Pigmentosa | Paris, France, January 10, 2018, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative dis... |
| - | GenSight Biologics reports its cash position as of September 30, 2016 | Source: Gensight |
| - | GenSight Biologics announces topline results from REVERSE Phase III clinical trial of GS010 in patients with Leber Hereditary Optic Neuropathy (LHON) | Paris, France, April 3, 2018, 5.35 pm CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseas... |
| - | GenSight Biologics Appoints Elsy Boglioli to its Board of Directors | Paris, France, October 14, 2020, 7:30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerativ... |
| - | GenSight Biologics to Present Data on GS010 and GS030 at the 2017 Congress of the European Society of Gene & Cell Therapy | Paris, France, October 16, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and d... |
| - | GenSight Biologics provides an update on the clinical and regulatory pathways for GS010 | Paris, France, September 13, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative ... |
| - | GenSight Biologics draws down the €4 million second tranche of bonds from Kreos Capital | Paris, France, August 4, 2020, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (the “Company” or “GenSight“), a biopharma company focused on discovering and developing innovative gene therapies for ... |
| - | GenSight Biologics announces positive Data Safety Monitoring Board review and continuation of PIONEER Phase I/II clinical trial of GS030 combining gene therapy and Optogenetics for the treatment of Re... | Paris, France, May 7, 2019, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disease... |
| - | GenSight Biologics Reports Cash Position as of March 31, 2020 and Provides Operational Update | Paris, France, April 21, 2020, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative dise... |
| - | Key Opinion Leaders highlight GS010 efficacy and patient benefits in discussion of findings from Reverse Phase III clincal trial | Paris, France, June 20, 2018, 7.30 am CEST – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative disea... |
| - | GenSight Biologics Appoints Barrett Katz as Chief Medical Officer | Paris, France, October 25, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and d... |
| - | GenSight Biologics Enrolls First Patient in Pivotal Phase III Program of GS010 in Leber’s Hereditary Optic Neuropathy | GenSight Biologics S.A. (GenSight), a clinical-stage biotechnology company discovering and developing novel gene therapies for neurodegenerative retinal diseases, and in the future, of the central nervous system, today announced enrollment ... |
| - | GenSight Biologics reports positive long-term visual acuity gains and safety results from Phase I/II Study of GS010 for the treatment of Leber Hereditary Optic Neuropathy (LHON) | Sustained clinically significant improvement of visual acuity at 2.5 years of follow-up in LHON patients with less than 2 years of onset of visual loss prior to treatment
Confirmation of the favorable long-term safety profile of GS010
Par... |
| - | GenSight Biologics announces presentation of bilateral visual recovery from GS010 (LUMEVOQ™) Phase III trials at the 46th annual meeting of NANOS | Paris, France, March 3, 2020, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseas... |
| - | GenSight Biologics announces publication of positive data from Phase I/II trial and long-term follow-up of GS010 in Ophthalmology, the journal of the American Academy of Ophthalmology | Paris, France, February 20, 2018, 7.30 am CET – GenSight Biologics (Euronext: SIGHT, ISIN:
FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing
innovative gene therapies for retinal neurodegenerative ... |
| - | GenSight Biologics receives Orphan Drug Designation and Advanced Therapy Medicinal Product classification in Europe for GS030 in Retinitis Pigmentosa | The European Medicines Agency (EMA), has granted orphan drug designation (ODD) to the Company’s product candidate GS030 for the treatment of retinitis pigmentosa. The EMA also granted Advanced Therapy Medicinal Product (ATMP) classification... |
| - | GenSight Biologics announces additional promising results of its Phase I/II study with GS010 for the treatment of Leber’s Hereditary Optic Neuropathy (LHON) | Confirmation of the good safety and tolerability profile of GS010
Improvement of visual acuity in patients with an onset of disease
of less than 2 years
Download pdf
Paris, 8 June 2016 – GenSight Biologics, a biotechnology company disco... |
| - | GenSight Biologics Reports its Cash Position as of September 30, 2017 | Paris, France, October 26, 2017, 7.30am CET – GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company that discovers and develops innovative gene therapies for neurodegenerative retinal diseases and d... |
| - | GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021 | PARIS--(BUSINESS WIRE)--Mar 10, 2021--
Regulatory News:
GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retina... |
| - | GenSight Biologics Closes $36 Million Series B Preferred Stock Financing | Paris, France, July 23rd, 2015 – GenSight Biologics S.A. (Gensight), a clinical-stage biotechnology company discovering and developing novel therapies for mitochondrial and neurodegenerative diseases of the eye, and in the future, of the ce... |
| - | GenSight Biologics S A : successfully raises €25 million in an oversubscribed private placement with US and European institutional investors | Paris, France, October 22 2020, 6.30 am CEST
The following information is not intended for, and may not be accessed by, or distributed or disseminated to, persons resident or physically present in the United States of America (including it... |
